---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035170"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:19:19.708273+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Praxis CCO Nicole Sweeny departs; cash runway extended to Q2 2024 via restructuring

## Summary
- Nicole Sweeny, Chief Commercial Officer, to depart effective March 31, 2023; no dispute or disagreement cited.
- Separation agreement provides 9 months base salary ($337,500) plus COBRA premium subsidy.
- Company refocuses on ulixacaltamide end-of-Phase-2 FDA meeting, PRAX-562 and PRAX-222 readouts.
- Realigned expenses and headcount expected to extend cash runway into Q2 2024.

## SEC filing metadata
- accession: 0001104659-23-035170
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/0001104659-23-035170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/tm239181d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035170
- JSON: https://secwatch.observer/filing/0001104659-23-035170.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035170.txt

## Key facts
- Executive change
  Nicole Sweeny departed as Chief Commercial Officer at Praxis Precision Medicines, Inc..
  - Action: departed
  - Role: Chief Commercial Officer
  source text: On March 17, 2023, Nicole Sweeny, Chief Commercial Officer of Praxis Precision Medicines, Inc. (the “Company”), and the Company determined that, considering the current priorities of the Company, Ms. Sweeny would depart from the Company, effective March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000110465923035170/0001104659-23-035170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.